Abstract
The bioavailability of biochemical bone turnover markers (BTM) (formation and resorption) that can be measured quickly and at a relatively low cost are an advantage in the evaluation and treatment of patients with metabolic bone diseases, especially osteoporosis. BTM provide a dynamic evaluation of the bone system which could potentially complement the static measurement of bone mineral density. However, it is necessary to know their limitations and use them in an appropriate clinical context. Currently, the clinical use of BTM is to monitor the efficacy of antiosteoporotic therapy. BTM could potentially have other functions, such as the prediction of treatment response and control of compliance with and appropriate use of the treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have